Skip to main content
Fig. 4 | Clinical Epigenetics

Fig. 4

From: BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes

Fig. 4

Apabetalone treatment decreased BRD4 occupancy at transcription regulatory elements of IFNγ-responsive genes. IFNγ stimulation (4 h) increases BRD4 occupancy on the CXCL10 and ICAM1 gene regulatory regions, but not in a BRD4 protein-lacking region (Control) as determined by chromatin immunoprecipitation (ChIP). Co-treatment with apabetalone (25 μM) reduces BRD4 association with gene regulatory regions. b Apabetalone (25 μM) also suppressed CXCL10 mRNA transcript induction by IFNγ in these same samples. Samples were processed in triplicate. Data are presented as the mean ± S.D. Statistical significance was determined through ANOVA followed by Tukey’s Multiple Comparison Test, where **p < 0.01, ***p < 0.001 and ns, no significant difference

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us